Please login to the form below
Avonex
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.
Biogen Idec board may sell
Biogen's primary drug portfolio consists of multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), as well as rheumatoid arthritis (RA) and cancer drug Rituxan (rituximab).
PMEA 2006: Winners in pictures
Avonex: How clear thinking and teamwork dramatically turned around the fortunes of a mature brand.
IPA Best of Health Awards
entry. agency. silver. Avonex - Shoe Box. Seven Stones. Idrolax - The Required Effect.
Biogen Q3 FY07 net profit falls nearly a quarter
MS drugs disappoint. Sales for Avonex (interferon beta-1a) increased 2.2 per cent to reach USD 454.9m.
Teva begins second Phase III trial of oral MS treatment
It will evaluate the safety, tolerability and effectiveness of laquinimod and produce risk-benefit data for laquinimod versus Avonex, an injectable treatment.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- Rare Disease Day in a COVID-19 environment
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
